Abstract
Public health need versus sales of antibacterial agents active against multidrug-resistant bacteria: a historical perspective
Highlights
Mg/kg Valganciclovir mg/kg was switched to oral valganciclovir at a dose of 150 mg twice daily, and the AUC0 – 12 was 24.5 mg.h/L
At the 1 year follow-up, a CMV test was still negative and no relapse of nephrotic syndrome was noticed. This case report emphasizes the importance of dosage individualization of ganciclovir and valganciclovir, taking into account pharmacokinetic changes associated with renal disease
We add to the current knowledge base on this issue by providing a historical perspective on the public health need for antibacterial agents active against emerging multidrug-resistant bacteria and the sales of selected agents, chosen as examples, that responded to this need in previous decades
Summary
Mg/kg Valganciclovir mg/kg was switched to oral valganciclovir at a dose of 150 mg twice daily, and the AUC0 – 12 was 24.5 mg.h/L. Public health need versus sales of antibacterial agents active against multidrug-resistant bacteria: a historical perspective
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
